Last update: Dec. 24, 2018
Safe. Compatible.
Minimal risk for breastfeeding and infant.
We do not have alternatives for Δεσφερριοξαμίνη Μεθυλοθειονική since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Δεσφερριοξαμίνη Μεθυλοθειονική is Deferoxamine in Greek.
Is written in other languages:Δεσφερριοξαμίνη Μεθυλοθειονική is also known as
Δεσφερριοξαμίνη Μεθυλοθειονική belongs to this group or family:
Main tradenames from several countries containing Δεσφερριοξαμίνη Μεθυλοθειονική in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | < 2 | % |
Molecular weight | 659 | daltons |
Protein Binding | < 10 | % |
VD | 1,33 | l/Kg |
pKa | 8,39 | - |
Tmax | 0,5 | hours |
T1/2 | 2 - 6 | hours |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
An iron and aluminum chelator that increases the elimination of both metals from the body.
Used over short periods to treat acute poisoning from these metals and, over longer periods, to treat chronic iron overload, hemochromatosis, hemosiderosis from repeated transfusions due to thalassemia major or other chronic anemias.
Administered subcutaneously, intramuscularly and intravenously.
At least three cases have been reported of infants of mothers suffering from thalassemia major who were treated with deferoxamine and breast-fed without any problems for the infant or in the iron metabolism of the milk (Pafumi 2000, Surbek 1998).
Its low percentage of protein binding makes its excretion in milk possible, but its practically zero oral bioavailability prevents its transfer to the infant’s plasma via ingested breast milk, except in premature babies and the immediate neonatal period in which there may be increased intestinal permeability.
According to expert authors, the possible presence of deferoxamine in breast milk is unlikely to have harmful effects in the infant (Briggs 2017, Pafumi 2000, Jensen 1995) so there is no reason to stop breastfeeding during treatment.
It may be advisable to control the infant’s serum iron levels.